KFDA announces Novartis Korea's verteporphin as first bulk drug at eligible foreign plant

The Korea Food and Drug Administration notified via Internet on April 28 that Novartis Korea's verteporphin (drug for the treatment of age-related macular degeneration) is the first pharmaceutical bulk material produced at an eligible manufacturing presence since the implementation of the current bulk material notification system since its implementation on July 2002.

The KFDA noted that thi...